title: Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours.
abstract: BACKGROUND
  The aim of this study was to assess the efficacy and toxicity of peptide receptor radionuclide therapy (PRRT) with the use of the high affinity somatostatin receptor subtype 2 analogue, (90)Y labelled Tyr3-octreotate, ((90)Y-DOTATATE) in neuroendocrine tumours (NETs).
  
  
  METHODS
  46 patients with disseminated or non-operable NET were enrolled in this study. The (90)Y-DOTATATE therapeutic activity was calculated per total body surface area up to a total of 7.4 GBq/m(2) administered in three to five cycles, repeated every four to nine weeks. Before and after the therapy, blood tests for haematology, kidney and liver function, and chromogranin A were performed.
  
  
  RESULTS
  Out of 46 (90)Y-DOTATATE treated patients, one died before completing the therapy and 16 died after completing the therapy, among them one due to myocardial infarction. After 12 month follow-up, stabilisation of disease was observed in 47%, partial remission in 31%, and progression in 9% of the 45 patients who completed the therapy. Five patients died before completion of 12 months of follow-up. One of the patients died due to myocardial infarction. In one case, the information after 12 months is incomplete. The progression free survival was 37.4 months. During 12 months follow-up, transient decrease of PLT, WBC and haemoglobin values was observed. A transient increase of creatinine level (within normal ranges) and decrease of GFR values were found.
  
  
  CONCLUSIONS
  NETs (90)Y-DOTATATE therapy results in symptomatic relief and tumour mass reduction. The mild critical organ toxicity does not limit the PRRT of NETs.
authors: Endocrinology Department, Jagiellonian University Medical College, Krakow, Poland.
authors: Anna
authors: A
authors: Sowa-Staszczak
authors: Dorota
authors: D
authors: Pach
authors: Jolanta
authors: J
authors: Kunikowska
authors: Leszek
authors: L
authors: Krolicki
authors: Agnieszka
authors: A
authors: Stefanska
authors: Monika
authors: M
authors: Tomaszuk
authors: Monika
authors: M
authors: Buziak-Bereza
authors: Renata
authors: R
authors: Mikolajczak
authors: Marta
authors: M
authors: Matyja
authors: Aleksandra
authors: A
authors: Gilis-Januszewska
authors: Agata
authors: A
authors: Jabrocka-Hybel
authors: Malgorzata
authors: M
authors: Trofimiuk
authors: Alicja
authors: A
authors: Hubalewska-Dydejczyk
mesh_terms: D000328:Adult; D000368:Aged; D018278:Carcinoma, Neuroendocrine; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000473:pathology / Q000532:radiotherapy*; D015282:Octreotide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D013223:Statistics as Topic; D013964:Thyroid Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: C539274:90Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)-; D009942:Organometallic Compounds; D015021:Yttrium Radioisotopes; D015282:Octreotide